Biora Therapeutics, Inc. to Post Q2 2023 Earnings of ($1.60) Per Share, HC Wainwright Forecasts (NASDAQ:BIOR)

Posted by on May 18th, 2023

Biora Therapeutics, Inc. (NASDAQ:BIOR – Get Rating) – Equities research analysts at HC Wainwright issued their Q2 2023 EPS estimates for Biora Therapeutics in a research note issued to investors on Tuesday, May 16th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings per share of ($1.60) for the quarter. The consensus estimate for Biora Therapeutics’ current full-year earnings is ($8.55) per share. HC Wainwright also issued estimates for Biora Therapeutics’ Q3 2023 earnings at ($1.67) EPS and Q4 2023 earnings at ($1.82) EPS.

Biora Therapeutics Trading Down 3.2 %

Shares of BIOR opened at $3.32 on Wednesday. Biora Therapeutics has a 12 month low of $1.95 and a 12 month high of $28.75. The firm’s 50 day moving average is $2.72 and its 200-day moving average is $47.41. The stock has a market capitalization of $39.38 million, a PE ratio of -0.70 and a beta of 1.24.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp bought a new position in shares of Biora Therapeutics during the third quarter worth approximately $27,000. Virtu Financial LLC bought a new position in Biora Therapeutics in the first quarter valued at approximately $29,000. WealthTrust Axiom LLC bought a new position in Biora Therapeutics in the fourth quarter valued at approximately $33,000. CIBC Asset Management Inc bought a new position in Biora Therapeutics in the first quarter valued at approximately $42,000. Finally, Commonwealth Equity Services LLC bought a new position in Biora Therapeutics in the third quarter valued at approximately $63,000. 54.13% of the stock is owned by institutional investors.

About Biora Therapeutics

(Get Rating)

Biora Therapeutics, Inc, a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake.

Featured Stories

Receive News & Ratings for Biora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.